Pretransplant Type 2 Hepatorenal Syndrome Is Associated with Persistently Impaired Renal Function after Liver Transplantation

Transplantation

Volumn 99, Issue 7, 2015, Pages 1441-1446

  Tan, Hiang K ^a   Marquez, Max ^a   Wong, Florence ^a   Renner, Eberhard L ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CASE CONTROL STUDY; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHROCYTE TRANSFUSION; FEMALE; GLOMERULUS FILTRATION RATE; HEPATORENAL SYNDROME; HEPATORENAL SYNDROME TYPE 2; HUMAN; INTENSIVE CARE UNIT; KIDNEY DYSFUNCTION; LENGTH OF STAY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; ADVERSE EFFECTS; CHI SQUARE DISTRIBUTION; COMPLICATION; CONVALESCENCE; END STAGE LIVER DISEASE; KAPLAN MEIER METHOD; KIDNEY; MORTALITY; MULTIVARIATE ANALYSIS; ODDS RATIO; OPERATIVE BLOOD LOSS; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

IMMUNOSUPPRESSIVE AGENT;

BLOOD LOSS, SURGICAL; CHI-SQUARE DISTRIBUTION; END STAGE LIVER DISEASE; ERYTHROCYTE TRANSFUSION; FEMALE; GLOMERULAR FILTRATION RATE; HEPATORENAL SYNDROME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY; LENGTH OF STAY; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RECOVERY OF FUNCTION; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84940719459     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000557     Document Type: Article

References (32)

1. Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predicts prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology. 2005;41:1282.
2. Ghosh S, Choudhary NS, Sharma AK, et al. Noradrenaline vs. terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int. 2013;33:1187.
3. Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol. 2009;43:680.
4. Brensing KA, Textor J, Perz J. Long term outcome after transjugular intrahepatic portosystemic shunt in non-transplant cirrhotic with hepatorenal syndrome: a phase II study. Gut. 2000;47:288.
5. Testino G, Ferro C, Sumberaz A. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stentshunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology. 2003;50:1753.
6. Wong F. Recent advances in our understanding of hepatorenal syndrome. Nat Rev Gastroenterol Hepatol. 2012;9:382.
7. Arroyo V, Fenandez J, Ginès P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis. 2008;28:81.
8. Rimola A, Gaveler JS, Schade RR, el-Lankany S, Starzl TE, Van Thiel DH. Effects of renal impairment on liver transplantation. Gastroenterology. 1987;93:148.
9. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology. 2002;35:1179.
10. Gonwa TA, McBride MA, Anderson K, Mai ML, Wadei H, Ahsan N. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us Am J Transplant. 2006;6:2651.
11. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931.
12. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl. 2003;9:741.
13. Iwatsuki S, Starzl TE, Todo S, et al. Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc. 1988;20:498.
14. Al Riyami D, Alam A, Badovinac K, Ivis F, Trpeski L, Cantarovich M. Decreased survival in liver transplant patients requiring chronic dialysis: a Canadian experience. Transplantation. 2008;85:1277.
15. Nadim MK, Genyk YS, Tokin C, Marrero JA, Fontana RJ, Lok AS. Impact of etiology of acute kidney injury on outcomes following liver transplantation: acute tubular necrosis versus hepatorenal syndrome. Liver Transpl. 2012;18:539.
16. Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl. 2011;17:1328.
17. Chok KS, Fung JY, Chan SC, et al. Outcomes of living donor liver transplantation for patients with preoperative type 1 hepatorenal syndrome and acute hepatic decompensation. Liver Transpl. 2012; 18:3035.
18. Restuccia T, Ortega R, Guevara M, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcomes. A case control study. J Hepatol. 2004;40:140.
19. Ruiz R, Barri YM, Jennings LW, et al. Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT). Liver Transpl. 2007;13:838.
20. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. The diagnosis, treatment and prevention of hepatorenal syndrome. Gut. 2007;56:1310.
21. KDOQIClinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1.
22. Selzner N, Girgah N, Lilly L, et al. The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to donor age. Liver Transpl. 2008;14:1778.
23. Demetris AJ, Batts KP, Dhillon AP, et al. Banff schema for grading of liver allograft rejection: an international consensus document. Hepatology. 1997;25:658.
24. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation. 1995;59:361.
25. Zhou XJ, Rakheja D, Yu X, Saxena R, Vaziri ND, Silva FG. The aging kidney. Kidney Int. 2008;74:710.
26. Bajaj JS, O'Leary JG, Reddy KR, et al. Differences in creatinine between genders could disadvantage infected cirrhotic women: the NACSELD experience. [Abstract]. J Hepatol. 2014;60:S389.
27. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42:439.
28. Teperman L, Moonka D, Sebastian A, et al. Calcineurin inhibitor-free mycophenolate/sirolimus maintenance in liver transplantation: the randomized Spare-the Nephron trial. Liver Transpl. 2013;19:675.
29. Neuberger JM, Mamelok RD, Neuhaus P, et al. Delayed introduction of reduced-dose tacrolimus and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant. 2009;9:327.
30. Boudjema K, Camus C, Saliba F, et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard dose tacrolimus in liver transplantation: a randomized study. Am J Transplant. 2011;11:565.
31. Cassinello C,Moreno E,Gozalo A, Ortunõ B,Cuenca B, Solís-Herruzo JA. Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis. Dig Dis Sci. 2003; 48:179.
32. deMattos AM, Olyaei AJ, BennettWM.Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis. 2000;35:333.